1·Bevacizumab treatment was associated with a low rate of serious adverse events.
贝伐单抗治疗法与低概率的严重不良反应有关。
2·Causes of death were predominantly due to lung cancer, but 14 patients in the bevacizumab group and 2 in the control group died as a result of drug toxicity.
尽管导致患者死亡的原因主要是肺癌，但是贝伐单抗组的14名患者以及对照组的2名患者却死于药物毒性。
3·Treatment with the chemotherapeutic agent bevacizumab, a humanized mab that neutralizes vascular endothelial growth factor, can lead to proteinuria and renal damage.
采用化学治疗药物(贝伐单抗，是中和血管内皮生长因子的人源化抗体)治疗可导致蛋白尿和肾功能损害。
4·Fortuitously, these drugs also have clinically obvious pharmacodynamic end points-hypertension for bevacizumab and skin toxicity for erlotinib and gefitinib.
例外的是，这些药物也有临床明显的药物副作用——贝伐单抗可致高血压，吉非替尼和厄洛替尼可有皮肤毒性。
5·Bevacizumab is given intravenously every two to three weeks.
贝伐单抗是静脉给予每两至三个星期。